Coulter Partners places three Board Directors at Our Future Health Trading Ltd

Our Future Health is an ambitious collaboration between the public, charity and private sectors to build the UK’s largest health research program – bringing people together to develop new ways to prevent, detect and treat disease. The Board of Trustees of Our Future Health, who are responsible for the charity’s policies, activities and assets, established a trading subsidiary, Our Future Health Trading Limited, which carries out specific activities in furtherance of the organization’s objectives - entering into funding agreements, licensing access rights, and entering into translational research projects with external parties.

“It has been our privilege to work with Coulter Partners over the last six months with our recruitment of three Non-Executive Directors. It was evident after the first meeting that they understood our needs and rapidly helped us secure three outstanding NEDs to join our board,” said Dr Andrew Roddam, CEO of Our Future Health.

“They were meticulous, extremely professional and an absolute pleasure to work with throughout the whole process.” he added.

Cristina is Chief Digital Health Officer, R&D at AstraZeneca, a global role covering all therapeutic areas within the organization. She has held several senior leadership roles across AstraZeneca over the last 13 years, including global commercial, in-country commercial, global finance and transformation roles. Before this, Cristina was a senior management consultant at Accenture, leading large transformation programs. She currently contributes to courses at Cambridge University to prepare the next generation of innovators, clinicians and researchers to embrace digital health. She provides keynotes at conferences such as the Digital Health World congress, the Royal Society of Medicine and The Financial Times. Cristina is also a chartered accountant (CIMA) and has completed the MIT leading enterprise transformation program.

Andy is currently Chair of Arecor Therapeutics pls, Ieso Digital Health, Congenica, Closed Loop Medicine and Owlstone Medical. He is a director of Cancer Research Horizons (CRUK), council member of the UKRI MRC and an advisor to several investment funds. Andy graduated from Cambridge with a PhD in Chemistry, and his early career spanned positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until 1999, and since then has founded, invested in and helped to scale over 30 innovative ventures including Vectura, Abcodia, Arakis, Cambridge Biotechnology Ltd and Geneservice. He is also a founder member of the Cambridge Angels. Andy received his CBE for services to life sciences in 2015.

Simon has over 40 years’ experience in the pharmaceutical industry and is currently chairing four biotechnology companies in the UK, Switzerland, Belgium and the United States. He also runs his family investment fund and consultancy company, as well as being a Trustee of Weizmann UK. Simon joined Kymab, a UK biotechnology company, as CEO in 2019, before selling it to Sanofi two years later. Before Kymab, Simon spent six years at Merck in Germany as COO of the healthcare division. He was also a member of the healthcare executive committee. Simon received his BSc in Biology from the University of Sussex before embarking on his career in the pharmaceutical industry and founding various successful biotechnology companies.

About Our Future Health Trading Ltd

Our Future Health is an ambitious collaboration between the public, charity and private sectors to build the UK’s largest health research program – bringing people together to develop new ways to prevent, detect and treat disease.

For more information, please visit https://ourfuturehealth.org.uk